Jun 10, 2021 / 08:00PM GMT
Brian M. Culley - Lineage Cell Therapeutics, Inc. - CEO, Interim CFO, President & Director
Good afternoon, everyone. My name is Brian Culley. I'm the Chief Executive Officer of Lineage Cell Therapeutics. I'd like to welcome you to a very special webinar today.
Before I begin, I'll refer you all to our safe harbor clause as I or other Lineage executives may make some forward-looking statements today, and you can learn more about our risk factors through our filings with the Securities and Exchange Commission at sec.gov.
Now I know many of you were expecting us to report our 6-month interim data for OpRegen, but we've moved that update to next month in order to make room for something far more exciting. As you all know, we have reported that an earlier observation of retinal tissue restoration has been repeated in 2 additional patients on the OpRegen clinical trial. So we believe this is much more than just an exciting clinical observation for these 3 individuals. We believe this first-of-its-kind data using a replace-and-restore approach represents a new paradigm for how the
Lineage Cell Therapeutics Inc Webinar Featuring External Therapeutic Area Experts Transcript
Feb 14, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers